Abivax S.A.: Results of the ABTECT Study Part 2 Trigger 36% Share Price Increase - Is This the Starting Shot for a Bigger Move?

Positive data for Obefazimod in hard-to-treat ulcerative colitis demonstrate sustained efficacy. The confirmed safety profile without increased malignancy rates minimizes regulatory market risks. The submission of the FDA approval application in the fourth quarter of 2026 remains the central milestone for the company. Clinical Efficacy and Study Details Abivax S.A. has published current data on the second part of the ABTECT maintenance study for the drug Obefazimod against ulcerative colitis. From the company's perspective, the results...